Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences BPC 157 Banned: Key Facts on the Latest FDA Decision BPC 157 ORAL Beverly Hills Rejuvenation Center The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide